Introduction: To provide evidence-based guidance for the rati onal and safe prescripti on of biological therapies in children and adolescents with juvenile idiopathic arthriti s (JIAs), considering the latest available evidence and the new licensed biologics. Methods: Rheumatologists and Pediatricians with experti se in Pediatric Rheumatology updated the recommendati ons endorsed by the Portuguese Society of Rh...
Methods. We prospectively collected patient and disease characteristics from patients with JIA who started biological therapy. Adverse events were collected during the follow-up period. Predictors of response at 1 year and drug retention rates were assessed at 4 years of treatment for the first biologic agent.Results. A total of 812 JIA patients [65% females, mean age at JIA onset 6.9 years (s.d. 4.7)], 227 rec...